Japan Tobacco vs British American Tobacco: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Japan Tobacco Inc. (2914.JP)

Q3 202626 Jul – 25 Aug 2026

▲2▼2

JT lifts profit and dividend outlook as overseas tobacco booms, but regulation bites

Full-year profit and dividend guidance raised JT lifted its full-year net profit forecast to 644 billion yen, above analyst consensus, and raised the annual dividend to 272 yen. Stronger overseas cigarette sales drove the upgrade, giving investors more confidence in cash returns and supporting the share price.
This is the core new event that re-rated the stock this period.
Interim results show broad revenue and profit growth First-half revenue rose 17.7% and net profit jumped 35%, with tobacco revenue and profit up in every region, led by a 25.2% gain in Europe, the Middle East and Africa. The results confirmed the upgrade was backed by real sales, not accounting, and pushed shares to record highs.
It shows the fundamental business strength behind the guidance raise.
US regulatory edge goes to rival ZYN The FDA gave Philip Morris's ZYN pouches modified-risk status, the first for a nicotine pouch. That lets ZYN market itself as less harmful, while JT's competing pouches lack that label, putting JT at a disadvantage in the fast-growing US smoke-free category.
It is a new competitive and regulatory setback for JT's next-generation products.
Tougher tobacco rules and goodwill risk flagged The UK passed a bill banning cigarette sales to anyone born after 2009, a long-term threat to JT's customer base there. Analysts also note goodwill equals 34.4% of total assets, so any writedown could hit reported profit and temper the strong share run.
It is the main counterweight investors should weigh against the bullish guidance.

August 202626 Jul – 25 Aug 2026

▲2▼2

JT lifts profit and dividend outlook as overseas tobacco booms, but regulation bites

Full-year profit and dividend guidance raised JT lifted its full-year net profit forecast to 644 billion yen, above analyst consensus, and raised the annual dividend to 272 yen. Stronger overseas cigarette sales drove the upgrade, giving investors more confidence in cash returns and supporting the share price.
This is the core new event that re-rated the stock this period.
Interim results show broad revenue and profit growth First-half revenue rose 17.7% and net profit jumped 35%, with tobacco revenue and profit up in every region, led by a 25.2% gain in Europe, the Middle East and Africa. The results confirmed the upgrade was backed by real sales, not accounting, and pushed shares to record highs.
It shows the fundamental business strength behind the guidance raise.
US regulatory edge goes to rival ZYN The FDA gave Philip Morris's ZYN pouches modified-risk status, the first for a nicotine pouch. That lets ZYN market itself as less harmful, while JT's competing pouches lack that label, putting JT at a disadvantage in the fast-growing US smoke-free category.
It is a new competitive and regulatory setback for JT's next-generation products.
Tougher tobacco rules and goodwill risk flagged The UK passed a bill banning cigarette sales to anyone born after 2009, a long-term threat to JT's customer base there. Analysts also note goodwill equals 34.4% of total assets, so any writedown could hit reported profit and temper the strong share run.
It is the main counterweight investors should weigh against the bullish guidance.

Latest26 Jul – 25 Aug 2026

▲2▼2

JT lifts profit and dividend outlook as overseas tobacco booms, but regulation bites

Full-year profit and dividend guidance raised JT lifted its full-year net profit forecast to 644 billion yen, above analyst consensus, and raised the annual dividend to 272 yen. Stronger overseas cigarette sales drove the upgrade, giving investors more confidence in cash returns and supporting the share price.
This is the core new event that re-rated the stock this period.
Interim results show broad revenue and profit growth First-half revenue rose 17.7% and net profit jumped 35%, with tobacco revenue and profit up in every region, led by a 25.2% gain in Europe, the Middle East and Africa. The results confirmed the upgrade was backed by real sales, not accounting, and pushed shares to record highs.
It shows the fundamental business strength behind the guidance raise.
US regulatory edge goes to rival ZYN The FDA gave Philip Morris's ZYN pouches modified-risk status, the first for a nicotine pouch. That lets ZYN market itself as less harmful, while JT's competing pouches lack that label, putting JT at a disadvantage in the fast-growing US smoke-free category.
It is a new competitive and regulatory setback for JT's next-generation products.
Tougher tobacco rules and goodwill risk flagged The UK passed a bill banning cigarette sales to anyone born after 2009, a long-term threat to JT's customer base there. Analysts also note goodwill equals 34.4% of total assets, so any writedown could hit reported profit and temper the strong share run.
It is the main counterweight investors should weigh against the bullish guidance.

British American Tobacco PLC (BATS.LSE)

Q2 202626 Jun – 29 Jun 2026

▲1▼1

BAT cuts 9,000 jobs to save £600m, launches buyback

New share buyback announced BAT said it will launch another share buyback during its closed period before July 30 half-year results. Buybacks reduce the number of shares, which can lift the value of those remaining. The stock rose 2% on the news.
Directly explains a positive price move and shows management's confidence.
9,000 job cuts under Fit2Win BAT is cutting 9,000 jobs (5,500 directly, 3,500 outsourced) to save £600m a year by 2028. Cost savings can boost future profits, but the upfront costs and weak cigarette demand weigh on sentiment. The stock fell 2% on the day.
This is the main new event and explains both the cost-saving upside and the demand-driven downside.
Weaker traditional cigarette demand The restructuring is driven by falling demand for traditional cigarettes. BAT is investing more in smoke-free products like Vuse vapes and Velo pouches, aiming for over half of revenue from these alternatives. The shift pressures current sales but is necessary for long-term growth.
Highlights the underlying demand problem that forces the restructuring and affects future revenue.

June 202626 Jun – 29 Jun 2026

▲1▼1

BAT cuts 9,000 jobs to save £600m, launches buyback

New share buyback announced BAT said it will launch another share buyback during its closed period before July 30 half-year results. Buybacks reduce the number of shares, which can lift the value of those remaining. The stock rose 2% on the news.
Directly explains a positive price move and shows management's confidence.
9,000 job cuts under Fit2Win BAT is cutting 9,000 jobs (5,500 directly, 3,500 outsourced) to save £600m a year by 2028. Cost savings can boost future profits, but the upfront costs and weak cigarette demand weigh on sentiment. The stock fell 2% on the day.
This is the main new event and explains both the cost-saving upside and the demand-driven downside.
Weaker traditional cigarette demand The restructuring is driven by falling demand for traditional cigarettes. BAT is investing more in smoke-free products like Vuse vapes and Velo pouches, aiming for over half of revenue from these alternatives. The shift pressures current sales but is necessary for long-term growth.
Highlights the underlying demand problem that forces the restructuring and affects future revenue.

Latest26 Jun – 29 Jun 2026

▲1▼1

BAT cuts 9,000 jobs to save £600m, launches buyback

New share buyback announced BAT said it will launch another share buyback during its closed period before July 30 half-year results. Buybacks reduce the number of shares, which can lift the value of those remaining. The stock rose 2% on the news.
Directly explains a positive price move and shows management's confidence.
9,000 job cuts under Fit2Win BAT is cutting 9,000 jobs (5,500 directly, 3,500 outsourced) to save £600m a year by 2028. Cost savings can boost future profits, but the upfront costs and weak cigarette demand weigh on sentiment. The stock fell 2% on the day.
This is the main new event and explains both the cost-saving upside and the demand-driven downside.
Weaker traditional cigarette demand The restructuring is driven by falling demand for traditional cigarettes. BAT is investing more in smoke-free products like Vuse vapes and Velo pouches, aiming for over half of revenue from these alternatives. The shift pressures current sales but is necessary for long-term growth.
Highlights the underlying demand problem that forces the restructuring and affects future revenue.